Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW):483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(8)

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MlXhT4lv[XOnIFHzd4F6 MX2yOEBp NEXL[GlKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= M4rQc|I1PjRzMUCz
COLO205 M{nH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTHPYs4OiCq MkSzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> NEPIdpczPDZ2MUGwNy=>
U937 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XWR|czKGh? NVG1WY1uSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>? MX:yOFY1OTFyMx?=
MOLM13 NELJXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\6eoZtPzJiaB?= M4jt[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> NXH2VWdvOjR4NEGxNFM>
MOLM13 M3XvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfzXWM4OiCq MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO NVvVZ4g6OjR4NEGxNFM>
MDA-MB-435 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjINlQhcA>? NXrG[3g4UUN3ME2wMlE3KM7:TR?= MYexOVgxOTh|MR?=
K562 MofoR5l1d3SxeHnjJGF{e2G7 NIjYRoM6PiCq NGrYemlFVVOR M1Xkb2lEPTB;MjFOwG0> NFTVZ|QzPDRzN{W2Oi=>
DU145 M{XHeGN6fG:2b4jpZ{BCe3OjeR?= NHPJOm86PiCq MnnMSG1UVw>? M2q0dWlEPTB;Nz61JO69VQ>? M3jScFI1PDF5NU[2
MDA-MB-231 NGmweZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXHNUDPxE1? M3HFR|I1KGh? MY\EUXNQ MlfvR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl MXGyOFQyPzV4Nh?=
MCF7 NXXoVmtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorjNUDPxE1? MkDjNlQhcA>? Mlf1SG1UVw>? NIC4S|NE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> Mk[yNlQ1OTd3Nk[=
MCF7 M3zI[mtqdmG|ZTDBd5NigQ>? NES2R2Y2KM7:TR?= MWOyOEBp NX\ET|R4TE2VTx?= MoXXTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= M1rWflI1PDF5NU[2
MDA-MB-231 M3;McmtqdmG|ZTDBd5NigQ>? MYC1JO69VQ>? Mn\ZNlQhcA>? NX\Gemc3TE2VTx?= MlG0TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= MnPyNlQ1OTd3Nk[=
MDA-MB-231 M3XC[2Z2dmO2aX;uJGF{e2G7 MVmxMVExKM7:TR?= NWHqboY{OjRiaB?= NGLiTlFFVVOR M{jiR4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= MVSyOFQyPzV4Nh?=
MCF7 Mn\SSpVv[3Srb36gRZN{[Xl? NUXYWnFIOS1zMDFOwG0> M3X4T|I1KGh? MVTEUXNQ NXn5Wnlj\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MWSyOFQyPzV4Nh?=
MDA-MB-231 NVrJ[YdnTnWwY4Tpc44hSXO|YYm= NXP3eIwzOC53LUGg{txO MlPVOFghcA>? NYq2bIMzTE2VTx?= NVu1dVdjcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? NXHqS2tJOjR2MUe1OlY>
MCF7 NGi5[I5HfW6ldHnvckBCe3OjeR?= MXSwMlUuOSEQvF2= MXO0PEBp M3nQ[GROW09? NF;nOWlp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? MU[yOFQyPzV4Nh?=
697 NHi4fJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHXUGVKSzVyPUG0PE4{QCCwTR?= MXjTRW5ITVJ?
P12-ICHIKAWA MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonRTWM2OD17Nj6wOEBvVQ>? NF3yfXBUSU6JRWK=
NB69 M3y0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zvdWlEPTB;MU[xMlghdk1? M170THNCVkeHUh?=
EoL-1 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X3[2lEPTB;MUi3MlI3KG6P MnHiV2FPT0WU
BHT-101 NEDJZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzaeHh7UUN3ME2xPVgvOjVibl2= NIr4TIVUSU6JRWK=
SK-NEP-1 NUjYbYdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OzbmlEPTB;MkKwMlAzKG6P NEW3RYZUSU6JRWK=
MHH-NB-11 NH;OWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm3OHFKSzVyPUKyNE4yQSCwTR?= NWrBepRQW0GQR1XS
AsPC-1 M{K2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfxRmZKSzVyPUK1Nk42OyCwTR?= NILiU4lUSU6JRWK=
ES1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;zTWM2OD1{NU[uNlUhdk1? NXPrUHhvW0GQR1XS
LAMA-84 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S5c2lEPTB;MkW4MlE6KG6P M{XVZXNCVkeHUh?=
MOLT-16 M4j1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;s[ZhYUUN3ME2yOVgvPDlibl2= MoC3V2FPT0WU
ES7 NVXiVFM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLVTWM2OD1{N{OuNFkhdk1? MWDTRW5ITVJ?
KY821 NH[3UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT1c2lIUUN3ME2zNVQvOSCwTR?= MULTRW5ITVJ?
RT-112 M4DoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTRUFczUUN3ME2zNlEvODVibl2= NYX1dYxPW0GQR1XS
HL-60 NEDJPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7CUVJKSzVyPUO0NE43PiCwTR?= NEO1WodUSU6JRWK=
MOLT-4 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN2NT6xN{BvVQ>? M4LGOHNCVkeHUh?=
KARPAS-45 M37HUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf0UJhKSzVyPUO3Ok4yPiCwTR?= MlPXV2FPT0WU
SK-N-AS NW\HS5FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXUTWM2OD1|OEeuPFMhdk1? M1SzO3NCVkeHUh?=
CTB-1 M{DGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvnWXNKSzVyPUSwOU4xOiCwTR?= NFvISIpUSU6JRWK=
NKM-1 NVLSdmJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjofZZKSzVyPUSxNU45QSCwTR?= MW\TRW5ITVJ?
HTC-C3 M4TS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DPTWlEPTB;NEOyMlk2KG6P M{TwVnNCVkeHUh?=
BE-13 NYrOWJd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR2ND6yO{BvVQ>? MYHTRW5ITVJ?
KOSC-2 NYnMc2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnVeVJrUUN3ME20OlYvQSCwTR?= NYK0cHZOW0GQR1XS
NB14 NWHhV5NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XC[GlEPTB;NEizMlU5KG6P NVPndWFRW0GQR1XS
CAL-27 NFnmfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTR7ND61PUBvVQ>? NE\CRYpUSU6JRWK=
H9 NWHoR3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnjT4xmUUN3ME20PVUvPDNibl2= M1P5WHNCVkeHUh?=
RS4-11 NIfXbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXntTZVLUUN3ME21NFQvPzNibl2= MYLTRW5ITVJ?
PA-1 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX1eXpKSzVyPUWwPU45PiCwTR?= MmTyV2FPT0WU
MV-4-11 M1\OVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vGTGlEPTB;NUGzMlg2KG6P MXLTRW5ITVJ?
OS-RC-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\uTGlEPTB;NUKxMlYzKG6P NXfpSIVJW0GQR1XS
RPMI-8226 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTV{Nj64OkBvVQ>? NFPHUXNUSU6JRWK=
HGC-27 NU\i[Gc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPOTWM2OD13NkSuPVkhdk1? MUXTRW5ITVJ?
CHP-212 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTV7Mz61PUBvVQ>? NWeyO2dTW0GQR1XS
NB10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTGdIpKSzVyPUW5PU4yQCCwTR?= Mn3aV2FPT0WU
HH NFnDXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TORmlEPTB;NUm5MlQ{KG6P MXnTRW5ITVJ?
EW-16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\yTWM2OD14MEOuOVIhdk1? NEniUmVUSU6JRWK=
ES8 M{TtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTZyNT6yNUBvVQ>? NEnYUmpUSU6JRWK=
HAL-01 NH\rfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PYfmlEPTB;NkC1MlY4KG6P MYHTRW5ITVJ?
A204 M2rlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq3WHFbUUN3ME22N|MvQTFibl2= NUf0cldoW0GQR1XS
MHH-PREB-1 M3PnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljwTWM2OD14M{[uPVkhdk1? MVTTRW5ITVJ?
EM-2 M{GwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZ3MD62OEBvVQ>? NUPZdph6W0GQR1XS
BV-173 NYfDd2VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjZcm9rUUN3ME22OVIvPDhibl2= NXPUdpl4W0GQR1XS
ONS-76 M3LiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zPd2lEPTB;Nke3MlgzKG6P M2XPeHNCVkeHUh?=
KM-H2 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3BXopRUUN3ME22PVUvPTRibl2= MU\TRW5ITVJ?
D-263MG MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XH[2lEPTB;N{G3MlEzKG6P Ml30V2FPT0WU
ES3 NX:0R41zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3GTWM2OD15MkiuPVMhdk1? NUTjWVU2W0GQR1XS
VA-ES-BJ MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXnVnVHUUN3ME23N|IvOjdibl2= MkfxV2FPT0WU
NBsusSR NVHnWXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorGTWM2OD15NEKuPVkhdk1? NVrsblNJW0GQR1XS
NCI-H520 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHzTWM2OD15NE[uOVIhdk1? NYDWZ3UzW0GQR1XS
ES5 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13kT2lEPTB;N{WyMlghdk1? Ml7HV2FPT0WU
T-24 NH\ETGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDFWGRKSzVyPUe3PE44OSCwTR?= M3vmOHNCVkeHUh?=
SW962 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHxTWM2OD16MEiuOlMhdk1? NFf2W2hUSU6JRWK=
EW-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThyOD63OkBvVQ>? M1LhZ3NCVkeHUh?=
RXF393 M3;BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThzMj63PUBvVQ>? NVy4dpZFW0GQR1XS
U251 M{\2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LwfWlEPTB;OEGzMlg5KG6P MXnTRW5ITVJ?
CAMA-1 NVr5WHl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPvTWM2OD16M{OuPVQhdk1? MXjTRW5ITVJ?
JVM-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHvTYMzUUN3ME24OVEvPzhibl2= MlXCV2FPT0WU
COLO-800 M{TydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTh7Nz63PEBvVQ>? NEGwVHpUSU6JRWK=
OVCAR-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\sfVdtUUN3ME25NFAvOSCwTR?= MonzV2FPT0WU
LB1047-RCC NYrVRmRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTl{Nz61OkBvVQ>? NYHSdm9uW0GQR1XS
SW954 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHRc4JKSzVyPUmyPU41OSCwTR?= MlHzV2FPT0WU
J-RT3-T3-5 NYf0RZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zFb2lEPTB;OUO2MlA3KG6P Ml62V2FPT0WU
Mewo MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nuU2lEPTB;OUO2MlYhdk1? MV3TRW5ITVJ?
NCI-H1770 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTrTWM2OD17NECuOVUhdk1? M17TUnNCVkeHUh?=
HO-1-N-1 NHrkW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPrbo5KSzVyPUm2Nk45OSCwTR?= M{e4VXNCVkeHUh?=
HSC-3 M3nYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTl4Nj60PEBvVQ>? NYrwelg3W0GQR1XS
TYK-nu MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvBU41KSzVyPUm5PE4zPSCwTR?= M1\iVnNCVkeHUh?=
KYSE-150 NF23cXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37VUGlEPTB;MT6wNFA4PiEQvF2= MlrNV2FPT0WU
SN12C M4XKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDLWYo4UUN3ME2xMlAxQDd3IN88US=> NUHF[2wyW0GQR1XS
MOLT-13 NX7xRoNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMEG0NlEh|ryP MkCzV2FPT0WU
TE-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPETWM2OD1zLkC0PFEzKM7:TR?= MnG0V2FPT0WU
DB M122NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[ydGlEPTB;MT6wO|I4OyEQvF2= M3XtWHNCVkeHUh?=
CAL-39 M4XHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLxOYxKSzVyPUGuNFc2OjJizszN NHrRWWtUSU6JRWK=
A3-KAW NIq1clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:yPGlEPTB;MT6wPFQxQCEQvF2= M2DNUXNCVkeHUh?=
CHP-134 M1j2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHTWotKSzVyPUGuNVE5ODdizszN MlTzV2FPT0WU
TGW NH;ER4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zpemlEPTB;MT6xNlM6PSEQvF2= NXewemVzW0GQR1XS
QIMR-WIL NHnYdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknyTWM2OD1zLkGzNVM1KM7:TR?= MXTTRW5ITVJ?
NCI-SNU-1 NFfxbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwMU[zOVQh|ryP Mn:wV2FPT0WU
CGTH-W-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHWZ211UUN3ME2xMlE4OTh4IN88US=> MWLTRW5ITVJ?
MHH-ES-1 Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DESmlEPTB;MT6xO|k5PiEQvF2= NFi0WHZUSU6JRWK=
LB2241-RCC NYDNTIE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XGdGlEPTB;MT6xPFYzKM7:TR?= NEnZNJBUSU6JRWK=
ML-2 NX;0RlRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrXb2hzUUN3ME2xMlIxPzN2IN88US=> M{L3d3NCVkeHUh?=
COR-L23 NG\2Z3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T4NGlEPTB;MT6yNlk{OyEQvF2= MnjPV2FPT0WU
BFTC-905 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrVZW5iUUN3ME2xMlI1OjZ5IN88US=> NVHyeWQxW0GQR1XS
Hs-578-T NVfNbYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHNVZNKSzVyPUGuNlU5OTdizszN MV3TRW5ITVJ?
KG-1 NFzEN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nPdmlEPTB;MT6yOlY5PiEQvF2= MUTTRW5ITVJ?
HEL Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjyTJVKSzVyPUGuNlk{OzhizszN NVG0ZlcyW0GQR1XS
A549 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlntTWM2OD1zLkK5N|k6KM7:TR?= M4K3OHNCVkeHUh?=
COLO-741 NHj6PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fFOWlEPTB;MT6zNlA5QSEQvF2= NUDDUXVXW0GQR1XS
PC-3 NYD1O3E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DaeWlEPTB;MT6zOVIzOSEQvF2= NHfHeJRUSU6JRWK=
HOS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH3XpNMUUN3ME2xMlM2Ojl4IN88US=> NW\IZmdmW0GQR1XS
HT-1080 NVG4PI94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwM{e1NVkh|ryP Mny5V2FPT0WU
TE-8 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\vV4JKSzVyPUGuOFE4PzRizszN MoPvV2FPT0WU
BHY MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPrT4lKSzVyPUGuOFY6OjNizszN Mln5V2FPT0WU
BB65-RCC MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO3VGQ{UUN3ME2xMlUxPTJ6IN88US=> NXf1coc4W0GQR1XS
HN NHy1WVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHPeZBKSzVyPUGuOVQxPzFizszN MUjTRW5ITVJ?
NCI-H441 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHFTWM2OD1zLkW0PVA4KM7:TR?= NGqzNWZUSU6JRWK=
RPMI-8866 M1rDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvXUZdMUUN3ME2xMlU5PTB5IN88US=> NUTablBKW0GQR1XS
CAL-62 M3n0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwNkC4OlIh|ryP NIHibm5USU6JRWK=
MG-63 NVO0SpRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi0SFlKSzVyPUGuOlE5OTNizszN NFfjcmpUSU6JRWK=
SK-LU-1 NEnwS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwNkKxOVIh|ryP NVjH[lMyW0GQR1XS
BCPAP M1PXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6xTWM2OD1zLk[2OFU4KM7:TR?= MXzTRW5ITVJ?
22RV1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwNke4OFMh|ryP Ml\WV2FPT0WU
T47D NX74WHlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwNkiwOlEh|ryP MmHRV2FPT0WU
MSTO-211H MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO5N|BQUUN3ME2xMlY6PjB|IN88US=> MUTTRW5ITVJ?
DEL NHrUWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHxTWM2OD1zLkewNlc{KM7:TR?= MUnTRW5ITVJ?
H4 NFvHfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvWVphKSzVyPUGuO|MzOTJizszN MnTqV2FPT0WU
CAL-51 NHHnNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLxSmJrUUN3ME2xMlc1QDV3IN88US=> NYL4OGtjW0GQR1XS
ABC-1 NUX4T2dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjuN4NQUUN3ME2xMlc5PTh{IN88US=> NXjEdWJ1W0GQR1XS
MZ2-MEL NXfINpIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[3UWJKSzVyPUGuO|k2PDJizszN NGLsU2lUSU6JRWK=
YKG-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHD[ZBKSzVyPUGuPFExPjFizszN MYHTRW5ITVJ?
KM12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwOEG2NFIh|ryP MoLpV2FPT0WU
L-363 NXLqdVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL0TWM2OD1zLki3OFEzKM7:TR?= M3zseHNCVkeHUh?=
KU812 M2\0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXVTWM2OD1zLki5NlgzKM7:TR?= MYPTRW5ITVJ?
LOXIMVI MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwOUGyNlgh|ryP NHGwcIdUSU6JRWK=
G-401 NILFZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fmdWlEPTB;MT65NlQzQCEQvF2= MVLTRW5ITVJ?
SW780 NYOz[ZB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjFcmtKSzVyPUGuPVYzPDZizszN NF20NHBUSU6JRWK=
SW872 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzXXlBKSzVyPUGuPVg{OyEQvF2= NInId41USU6JRWK=
NB7 NEXiOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwOUmzNlMh|ryP MoW5V2FPT0WU
T98G MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DLR2lEPTB;Mj6wNFY3PiEQvF2= NV;Q[pQ6W0GQR1XS
SW1710 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwME[5OFUh|ryP MoDLV2FPT0WU
NCI-H1573 NYrYNFRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz2TWM2OD1{LkC3Nlk5KM7:TR?= NXi2VXh4W0GQR1XS
KE-37 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmeyTWM2OD1{LkC4PVUyKM7:TR?= NUPkXpFEW0GQR1XS
786-0 M3fTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj6NI5KSzVyPUKuNVU1OzlizszN MVnTRW5ITVJ?
SAS NYHpSlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny2TWM2OD1{LkKwN|c1KM7:TR?= MYHTRW5ITVJ?
CAL-54 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK2eJhKSzVyPUKuNlA1OTNizszN M4j2NXNCVkeHUh?=
SF268 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S2[mlEPTB;Mj6yN|EzOiEQvF2= MmP2V2FPT0WU
SW620 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwMk[xOlkh|ryP NWrie5lzW0GQR1XS
MN-60 NVGxbWJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7lZ21VUUN3ME2yMlMyODZizszN NELpO5ZUSU6JRWK=
EFO-27 NV7LbXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TVcGlEPTB;Mj6zNlA2QCEQvF2= MUDTRW5ITVJ?
NCI-H747 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwM{KxPVkh|ryP M4j0e3NCVkeHUh?=
HCC2218 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwM{WzO|Qh|ryP NGDieGNUSU6JRWK=
MIA-PaCa-2 NWDXRoxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HHTGlEPTB;Mj6zOlQ{PyEQvF2= MYnTRW5ITVJ?
SJSA-1 M2rCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTFd3ZIUUN3ME2yMlM4Pzl4IN88US=> NHTQbXBUSU6JRWK=
RKO NWnneVJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL3[JNRUUN3ME2yMlM5PDl4IN88US=> NVHF[Y9vW0GQR1XS
NB6 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwNECzO|Qh|ryP NX\DNZB1W0GQR1XS
ES4 NHjScVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOyNnBxUUN3ME2yMlQ2PDJ{IN88US=> NIe1VmFUSU6JRWK=
EGI-1 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTwUWFKSzVyPUKuOFY5QDNizszN NETWOXdUSU6JRWK=
CTV-1 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnPbHBZUUN3ME2yMlUzPzd|IN88US=> Ml;OV2FPT0WU
NCI-H1355 NYfxd4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJwNUW5OVEh|ryP M37OcHNCVkeHUh?=
GT3TKB NYnvbXl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPiSWNtUUN3ME2yMlU6OTl7IN88US=> MUTTRW5ITVJ?
SK-HEP-1 NUnkclQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJwNUmyOlYh|ryP NWHYdG1SW0GQR1XS
GAMG M1zsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXiTWM2OD1{LkW5N|k1KM7:TR?= MY\TRW5ITVJ?
SK-MES-1 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;jPGlEPTB;Mj62NVgxOyEQvF2= MVHTRW5ITVJ?
RO82-W-1 NY\ycXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJwNkKwOVch|ryP NUfvdGsyW0GQR1XS
ECC10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTzdId1UUN3ME2yMlcxOjB4IN88US=> MXfTRW5ITVJ?
MCF7 NWTtNmJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnhTWM2OD1{LkexOFY1KM7:TR?= MV3TRW5ITVJ?
D-283MED NVflTYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HjVmlEPTB;Mj63NlQ{KM7:TR?= Mo\rV2FPT0WU
RPMI-7951 M{nJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnWSItKSzVyPUKuO|U3QTRizszN M1H5WnNCVkeHUh?=
Ramos-2G6-4C10 NXHveFVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\LO|B3UUN3ME2yMlc4ODl7IN88US=> MXrTRW5ITVJ?
KGN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XzUmlEPTB;Mj64NVg5PCEQvF2= M1e1PXNCVkeHUh?=
NUGC-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj6[5BKSzVyPUKuPFI2ODVizszN NEnMT2hUSU6JRWK=
NCI-H292 M{TLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjITVFrUUN3ME2yMlg2ODV|IN88US=> NGX0e2VUSU6JRWK=
Becker NUD3bIJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPpZ|JKUUN3ME2yMlk2QDN{IN88US=> NInMNoxUSU6JRWK=
NCI-H1299 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNwMEWyOlMh|ryP MoXlV2FPT0WU
ETK-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnNT5RKSzVyPUOuNFU1OyEQvF2= MUjTRW5ITVJ?
TK10 NFz1UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLjb2NpUUN3ME2zMlIxOTZ3IN88US=> MnX6V2FPT0WU
VMRC-RCZ NEDUOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTYflFKSzVyPUOuN|Y1QDhizszN Ml\YV2FPT0WU
YH-13 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH2NHpJUUN3ME2zMlQ1ODd7IN88US=> NV3yc4xMW0GQR1XS
DU-145 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;vV3dKSzVyPUOuOFYzPjlizszN MUHTRW5ITVJ?
SW1088 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwNEe0O{DPxE1? MVvTRW5ITVJ?
HOP-92 NEHjelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXWTGZKSzVyPUOuOVA{PDJizszN M33jd3NCVkeHUh?=
KP-N-YS NF;tXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNwNkKxN|kh|ryP MkPjV2FPT0WU
NCI-H460 NXjEVYM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLm[HJKSzVyPUOuOlY4OyEQvF2= MVLTRW5ITVJ?
U-2-OS NEnocIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL1d4RwUUN3ME2zMlczPTN3IN88US=> NHzlOHdUSU6JRWK=
A101D NUTB[INzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG2NHRyUUN3ME2zMlc3QTN4IN88US=> NUj4Nms2W0GQR1XS
MDA-MB-231 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrVVppIUUN3ME2zMlgyQTVzIN88US=> MXzTRW5ITVJ?
IST-MES1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwOEOyJO69VQ>? MXXTRW5ITVJ?
COR-L105 NFvvN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTRwMEG4JO69VQ>? NIjTU29USU6JRWK=
NCI-H1437 M32xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRwMEKzNFIh|ryP M3;zbHNCVkeHUh?=
CAL-85-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfuSmZ{UUN3ME20MlAzPDZzIN88US=> NYfkZm5UW0GQR1XS
MZ1-PC NVj0WG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwMUi1OVYh|ryP NGn5eVFUSU6JRWK=
VM-CUB-1 NEPnVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK3dHB4UUN3ME20MlMyOjh2IN88US=> NUPoUnF4W0GQR1XS
CHL-1 M1q2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7QTWM2OD12LkOyNVY6KM7:TR?= NIq3ZVVUSU6JRWK=
MDA-MB-361 MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fqVGlEPTB;ND6zN|E2OyEQvF2= Ml\DV2FPT0WU
NCI-H661 M3jvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLQRm9KSzVyPUSuOVAxQTJizszN NWXXbmNvW0GQR1XS
EW-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP6TWM2OD12LkWyNlMyKM7:TR?= MXzTRW5ITVJ?
BEN MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljVTWM2OD12LkWyPFE2KM7:TR?= NVizWJczW0GQR1XS
BFTC-909 NXLwXGpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSwZlI2UUN3ME20MlU3Ojd3IN88US=> M1vyfnNCVkeHUh?=
NCI-H2087 NUT6XZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q2emlEPTB;ND61PFE3PCEQvF2= MonYV2FPT0WU
RVH-421 NX7vR2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL2TWM2OD12Lk[2Olkh|ryP NGnaSmtUSU6JRWK=
P30-OHK NH3tRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nqZ2lEPTB;ND62PFAxQCEQvF2= M1\oc3NCVkeHUh?=
NCI-H28 M{jTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S2N2lEPTB;ND64NVY3OSEQvF2= NVy3[mo4W0GQR1XS
ES6 M1TaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17wcGlEPTB;ND64N|AyPiEQvF2= MoDLV2FPT0WU
769-P NXHHU4hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvIUmRbUUN3ME20Mlg2QTJ4IN88US=> M13qTHNCVkeHUh?=
OE33 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXaTWM2OD12Lki4NVYyKM7:TR?= MmfqV2FPT0WU
SW982 M{HiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DsbmlEPTB;ND65OVA3OSEQvF2= MVnTRW5ITVJ?
A388 NEKxTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEezXnhKSzVyPUWuNFI6QDNizszN MmH5V2FPT0WU
TI-73 NVXHUY46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTVwME[xPVQh|ryP NYPYNpV6W0GQR1XS
HCT-116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTVwMEm4PFkh|ryP NYLzWoxUW0GQR1XS
HuP-T3 NV;G[Wt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTVwMUi3NFkh|ryP NIHKWIJUSU6JRWK=
G-402 M33o[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jDemlEPTB;NT6xPVQyPiEQvF2= NIK4SXZUSU6JRWK=
NCI-H1792 M1OyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[0TWM2OD13LkK0OlIzKM7:TR?= NUTkfFVUW0GQR1XS
NCI-H209 M1vzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfZc4N7UUN3ME21MlI2QTR{IN88US=> NUPCV|FtW0GQR1XS
NCI-H1650 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTVwM{C2N|Qh|ryP NGmzUYlUSU6JRWK=
LCLC-97TM1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVwM{G4NFgh|ryP MmfpV2FPT0WU
S-117 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHVbIlKSzVyPUWuN|Y6PzZizszN NXnpU41JW0GQR1XS
GI-ME-N MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G0c2lEPTB;NT6zPVY5OSEQvF2= MlXWV2FPT0WU
NCI-H2122 M1\DZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O2U2lEPTB;NT60PVM6PyEQvF2= MmTiV2FPT0WU
NCI-H1793 NXKyNlhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qyfGlEPTB;NT62O|U6OyEQvF2= NYCxZmlyW0GQR1XS
C2BBe1 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvMWFNKSzVyPUWuO|AxQDhizszN M1\aR3NCVkeHUh?=
TE-12 M37H[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTVwOEC1OVYh|ryP MoLaV2FPT0WU
LCLC-103H NU\3cGc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnUNW5KSzVyPUWuPVE4KM7:TR?= MYjTRW5ITVJ?
A673 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T2UGlEPTB;NT65NVk{OiEQvF2= NHLjOplUSU6JRWK=
BB30-HNC M161TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTVwOUizOkDPxE1? NFLy[IhUSU6JRWK=
SF295 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e1PGlEPTB;Nj6wNFQzOiEQvF2= MlzTV2FPT0WU
KU-19-19 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWizUop6UUN3ME22MlAyPzNzIN88US=> MYHTRW5ITVJ?
CFPAC-1 M4HHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTZwMES0OFMh|ryP M3PUNXNCVkeHUh?=
LoVo NXf0cGJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnLTWM2OD14LkC1NFY{KM7:TR?= M3fwO3NCVkeHUh?=
8505C M4nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHHfmxGUUN3ME22MlA4PTd|IN88US=> NWOxOJpnW0GQR1XS
GMS-10 NUH5PWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LyU2lEPTB;Nj6xOVAxOiEQvF2= MYfTRW5ITVJ?
Ca9-22 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTZwMU[3NUDPxE1? MkCzV2FPT0WU
DOK MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHueIFKSzVyPU[uNlIxPzJizszN NGHMWHRUSU6JRWK=
FADU Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHZdXZKSzVyPU[uNlYxOzlizszN MULTRW5ITVJ?
BxPC-3 NUflVGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTZwMkezNkDPxE1? MUTTRW5ITVJ?
CAL-33 NWHKWXJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rLXWlEPTB;Nj6yPVIxOSEQvF2= M2fBdnNCVkeHUh?=
SHP-77 NHrzXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\EN3lKSzVyPU[uN|E2OTJizszN MlmzV2FPT0WU
LXF-289 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLOTWM2OD14LkOzOFU2KM7:TR?= MYDTRW5ITVJ?
GB-1 NFzic2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v5UGlEPTB;Nj6zPFIh|ryP M2Pj[nNCVkeHUh?=
KS-1 MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VTlZKSzVyPU[uN|g1PDdizszN M{HQSHNCVkeHUh?=
D-502MG Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlyxTWM2OD14LkSyN|c3KM7:TR?= MoG3V2FPT0WU
LAN-6 M165NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZwNUGwNlMh|ryP NF;uNYJUSU6JRWK=
H-EMC-SS NIH1d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nSZmlEPTB;Nj61OlE1PyEQvF2= MXnTRW5ITVJ?
LC-2-ad MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfMUGtKSzVyPU[uOlAxPzZizszN MnziV2FPT0WU
NCI-H1693 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Htb2lEPTB;Nj62NlIyPSEQvF2= Mmi2V2FPT0WU
SK-N-FI MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vFTmlEPTB;Nj63OVA1PCEQvF2= MUXTRW5ITVJ?
D-423MG NHrLepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD14Lke2NVE4KM7:TR?= NFrLbnRUSU6JRWK=
KNS-42 NIDMXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HIT2lEPTB;Nj63PFE6PyEQvF2= NFP1TYtUSU6JRWK=
GCT MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjzZlNKSzVyPU[uPVM5KM7:TR?= MnXjV2FPT0WU
DSH1 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTdwME[zN{DPxE1? MmHkV2FPT0WU
D-247MG NUi1PJN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnZeY1KSzVyPUeuNFc5QDFizszN NFO1[HlUSU6JRWK=
NCI-SNU-5 M{exV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWWxTllwUUN3ME23MlE5OzdzIN88US=> MULTRW5ITVJ?
TE-6 M2TLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTdwMkC2NFEh|ryP NIC3SlNUSU6JRWK=
NOMO-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImyXZNKSzVyPUeuNlIyOjdizszN MVzTRW5ITVJ?
NB17 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvzTWM2OD15LkOwN|A6KM7:TR?= NHPTNpVUSU6JRWK=
EW-22 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTdwM{SzOFgh|ryP NXfMflhFW0GQR1XS
EW-13 NW\tfoZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTdwM{WxOlIh|ryP M3HYSXNCVkeHUh?=
DOHH-2 M2O2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTdwNESwNkDPxE1? NVLydJpGW0GQR1XS
TGBC1TKB NXjhVZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzMTWM2OD15LkS5PFk6KM7:TR?= NVTjVY5KW0GQR1XS
GR-ST NFvTXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr3RVVKSzVyPUeuOVI2QTRizszN NHTjO5FUSU6JRWK=
KYSE-520 M121[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjdlFKSzVyPUeuOVU2OTVizszN NFLOWFZUSU6JRWK=
CAPAN-1 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWyTYprUUN3ME23MlU6PTFizszN NWjMclF4W0GQR1XS
HCE-4 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT5T5dKSzVyPUeuOlIzPzlizszN NHjGXohUSU6JRWK=
MLMA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnFNXFKSzVyPUeuOlI6PTdizszN NHP5N2dUSU6JRWK=
HT-144 NF3UNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7FTWM2OD15Lk[1N|Y5KM7:TR?= NVvBTms{W0GQR1XS
KYSE-180 M2fOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQS5VKSzVyPUeuO|EyPjlizszN NIXZcJpUSU6JRWK=
TE-5 NEK0fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHHXXUyUUN3ME23Mlk2QTdzIN88US=> MoHIV2FPT0WU
IGROV-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vzUmlEPTB;Nz65PFU2OSEQvF2= MYrTRW5ITVJ?
NCI-H1581 NWm0cVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2xTWM2OD16LkCxNkDPxE1? MXfTRW5ITVJ?
SW1990 NGr0Wm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLQV4wyUUN3ME24MlA1PjV7IN88US=> MXvTRW5ITVJ?
EFM-19 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrYbYdsUUN3ME24MlA5PTR3IN88US=> MV\TRW5ITVJ?
OGR-1 NGXUVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPsOmVKSzVyPUiuOFMxOjNizszN MXzTRW5ITVJ?
U-118-MG NIHufZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRThwNEO0OlMh|ryP Mnm0V2FPT0WU
SK-OV-3 M{jRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PQR2lEPTB;OD60Olc3PSEQvF2= NH\MTJhUSU6JRWK=
KNS-62 M4XMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRThwNUG3OlEh|ryP Mln0V2FPT0WU
GOTO NUT5O|JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\0TWM2OD16LkW3OlM2KM7:TR?= NVvVUlF1W0GQR1XS
8305C NFHSNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDoTWM2OD16LkewOFg1KM7:TR?= NF7OcHNUSU6JRWK=
RPMI-2650 NGLYbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRThwN{G5OVUh|ryP NFHxXZVUSU6JRWK=
NEC8 M1vCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRThwN{SzNFch|ryP NHXWWFJUSU6JRWK=
KYSE-450 NX3tUm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfCRlRKSzVyPUiuPFY2PDhizszN MlrYV2FPT0WU
RMG-I NGLpWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTlwMUSwOVgh|ryP M1PRfHNCVkeHUh?=
CAKI-1 M3XHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTLTWM2OD17LkOxPVc6KM7:TR?= MY\TRW5ITVJ?
KYSE-510 NIrMXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTlwM{W3O|gh|ryP MXrTRW5ITVJ?
A4-Fuk MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\6PIFIUUN3ME25MlM3PzBzIN88US=> MkTFV2FPT0WU
AN3-CA MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTlwNEW0OFQh|ryP MnX6V2FPT0WU
SK-N-DZ NVjyeYw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P5OGlEPTB;OT63Nlg1QSEQvF2= MU\TRW5ITVJ?
HSC-2 NHHke5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXaRmpKSzVyPUmuO|Y3OjlizszN MoX6V2FPT0WU
EW-1 NH;OfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny0TWM2OD17Lke5N|Y6KM7:TR?= NWK0VYRbW0GQR1XS
D-566MG NIDPdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDRTWM2OD17LkizOlY1KM7:TR?= MmPuV2FPT0WU
COLO-792 NWPXNI0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml35TWM2OD17Lkm4O|Q3KM7:TR?= MX\TRW5ITVJ?
TE-10 M2nDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFyLkCzPVYh|ryP NH:3TGdUSU6JRWK=
NCI-H650 NUS5VnVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m2d2lEPTB;MUCuOFI5PiEQvF2= MVTTRW5ITVJ?
U-266 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H0ZWlEPTB;MUCuOFU2KM7:TR?= NH;CUXFUSU6JRWK=
Detroit562 NWDGdGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofITWM2OD1zMT6wOVE2KM7:TR?= MVXTRW5ITVJ?
NH-12 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;aTWM2OD1zMT6xOFQ3KM7:TR?= M1HkOXNCVkeHUh?=
CO-314 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFzLkK4OFIh|ryP NVficHhyW0GQR1XS
IST-MEL1 NY[wWGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[zZmlEPTB;MUGuOVMzOyEQvF2= NWXST2NYW0GQR1XS
KNS-81-FD NYfRS3BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFzLkW1Nlch|ryP NUDBOXpzW0GQR1XS
SW1463 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBU3NKSzVyPUGxMlU6QDlizszN MWfTRW5ITVJ?
NCI-H23 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[xTZNKSzVyPUGxMlY2PTJizszN M1PPOXNCVkeHUh?=
SK-MEL-2 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjyd25FUUN3ME2xNU44OTl5IN88US=> MoTRV2FPT0WU
NB13 NVPWcoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\kTWM2OD1zMj6xOFk2KM7:TR?= NHK5[5ZUSU6JRWK=
Daoy MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKx[lI1UUN3ME2xNk4zQDV4IN88US=> NF:wU4hUSU6JRWK=
NCI-H1623 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHRTWM2OD1zMj6zPFAyKM7:TR?= NFKwU5NUSU6JRWK=
NMC-G1 M2XpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[2NWlEPTB;MUKuO|E4KM7:TR?= NYXweG9bW0GQR1XS
DK-MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF{Lkm0PFIh|ryP M1zkV3NCVkeHUh?=
TCCSUP MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:1PW5KSzVyPUGzMlEzQDRizszN MUDTRW5ITVJ?
SCC-15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK5N5ViUUN3ME2xN{4zPjVzIN88US=> NW\BWoxxW0GQR1XS
NOS-1 NFXmXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHINmxEUUN3ME2xN{4zQDl|IN88US=> MX\TRW5ITVJ?
RH-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jlb2lEPTB;MUOuN|A{PyEQvF2= NUDKTllvW0GQR1XS
SK-MEL-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjJUIpKSzVyPUGzMlM4OjhizszN NX3W[Ig6W0GQR1XS
NB5 M3j5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF|LkSwOlch|ryP NF;I[29USU6JRWK=
SNU-387 NXrsN5FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS3TWM2OD1zMz61NFczKM7:TR?= MUPTRW5ITVJ?
CAL-120 NWLadJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnVUFE4UUN3ME2xN{43PzF6IN88US=> NFfCPY1USU6JRWK=
Mo-T MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV33UZdiUUN3ME2xN{44ODdizszN NIHBfFFUSU6JRWK=
LNCaP-Clone-FGC NGLGSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;oSWlEPTB;MUOuO|k6OiEQvF2= Mo\IV2FPT0WU
CAN MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLtUWRIUUN3ME2xOE4xOjh6IN88US=> NFH5d|hUSU6JRWK=
SK-MEL-30 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPtW4ZwUUN3ME2xOE4xPjNizszN NYHYUXYyW0GQR1XS
COLO-678 NEHQPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLjTWM2OD1zND6wPFIzKM7:TR?= NWP4bmxHW0GQR1XS
SCC-9 M3n5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZfWlEPTB;MUSuNVAzOSEQvF2= NFvtcXhUSU6JRWK=
KINGS-1 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zKfmlEPTB;MUSuNVQxOiEQvF2= MoD6V2FPT0WU
SL-513 NI\ad5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHHTWM2OD1zND6xPFch|ryP NVG4U5FRW0GQR1XS
HLE NVK1XXlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILheXRKSzVyPUG0MlM5PTJizszN MYLTRW5ITVJ?
SW1573 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF2LkS0N|Uh|ryP M12zc3NCVkeHUh?=
KYSE-140 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS4WIdxUUN3ME2xOE43OzJ5IN88US=> Mm\xV2FPT0WU
SK-PN-DW NGG5ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF2LkiwNFEh|ryP NFnV[ItUSU6JRWK=
A253 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTOTWM2OD1zNT6wOlI2KM7:TR?= NWH3TVRZW0GQR1XS
CAL-12T M{W0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF3LkS2OlIh|ryP Ml25V2FPT0WU
COLO-679 NGrjRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTIc2Q3UUN3ME2xOU44Pjh|IN88US=> M2[2R3NCVkeHUh?=
UACC-257 NX;sNJV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnYTWM2OD1zNj6xNlAyKM7:TR?= MV7TRW5ITVJ?
U-87-MG M1j3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvQTWM2OD1zNj6zOVI{KM7:TR?= NEjCVo1USU6JRWK=
HCC1806 NIrYfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\pWmlEPTB;MU[uO|A4OSEQvF2= MVvTRW5ITVJ?
NCI-H2170 NYjTcVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\0dGlEPTB;MUeuNlQ1QCEQvF2= NV;uO5B1W0GQR1XS
AGS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnQTWM2OD1zNz6zPFA5KM7:TR?= NFPEc4RUSU6JRWK=
MEL-HO MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjqd41bUUN3ME2xO{44PTB|IN88US=> NX\J[llqW0GQR1XS
SW48 NGfBeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjTXYJMUUN3ME2xO{44PzF4IN88US=> NEDrbohUSU6JRWK=
HuP-T4 NXj0bVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr1b2hKSzVyPUG4MlAzODZizszN MUTTRW5ITVJ?
NCI-H720 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLOTWM2OD1zOD6xOFAzKM7:TR?= NGGzSXJUSU6JRWK=
RCC10RGB M2rOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF6LkG2PVch|ryP MWDTRW5ITVJ?
HD-MY-Z NH;XdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT4TWM2OD1zOD6yNlU1KM7:TR?= MXPTRW5ITVJ?
A427 NU\0dmlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzPVVBKSzVyPUG4MlUxQTRizszN M2n4T3NCVkeHUh?=
HCC2998 NHrpV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mzSWlEPTB;MUiuOlA2OSEQvF2= M{XsRnNCVkeHUh?=
EPLC-272H M1HZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF7LkC0N|Qh|ryP NEjEWZVUSU6JRWK=
C32 NIjXO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF7LkC0OUDPxE1? M32wUnNCVkeHUh?=
UMC-11 MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHESWtWUUN3ME2xPU4zOTJ|IN88US=> M3;nUXNCVkeHUh?=
CaR-1 NFLJfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Rd2ZKSzVyPUG5MlY5ODRizszN M1m5[nNCVkeHUh?=
KYSE-410 M2HuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF7LkmxN|kh|ryP MXvTRW5ITVJ?
HuCCT1 NYrzd2JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXyZpFKSzVyPUKwMlYzQTRizszN MnSxV2FPT0WU
LB996-RCC Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXLTWM2OD1{MD63NVY5KM7:TR?= MmPCV2FPT0WU
KYSE-70 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DnfmlEPTB;MkCuPFA2QSEQvF2= M{[4PHNCVkeHUh?=
CAL-72 NVzH[3FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPqTWM2OD1{MD65NVUh|ryP Mom3V2FPT0WU
Capan-2 NYfnO2E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJzLkC0NVMh|ryP NV;6cW9LW0GQR1XS
PANC-08-13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnjVI9KSzVyPUKxMlI2OTVizszN NY[5eYEyW0GQR1XS
SBC-1 M3PZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj5fWdKSzVyPUKxMlMxQDFizszN NUTIdG17W0GQR1XS
MFM-223 NUjBTIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvKUo9xUUN3ME2yNU4{OzR{IN88US=> Mnq0V2FPT0WU
BB49-HNC NFfCZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7EbHRHUUN3ME2yNU42PzF4IN88US=> M4q3O3NCVkeHUh?=
SH-4 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjHOlJzUUN3ME2yNU43PjF6IN88US=> MX3TRW5ITVJ?
HuO9 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LKU2lEPTB;MkGuPVgzPSEQvF2= MVHTRW5ITVJ?
AM-38 NVT5cWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj6[25KSzVyPUKyMlA1QDVizszN M1LaNHNCVkeHUh?=
A431 NYLMVmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrxfZZEUUN3ME2yN{4zOTF7IN88US=> MUPTRW5ITVJ?
YAPC MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXntVplRUUN3ME2yN{4zPjVzIN88US=> MX3TRW5ITVJ?
LU-139 NGrDSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLYeYNzUUN3ME2yN{41QDB7IN88US=> NEHReWhUSU6JRWK=
HEC-1 NF7KZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wW|h7UUN3ME2yN{41QTN5IN88US=> MVTTRW5ITVJ?
SCC-25 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvnTWM2OD1{ND6zNFA3KM7:TR?= M{HyV3NCVkeHUh?=
HT-29 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrYTWM2OD1{ND6zPFI{KM7:TR?= MleyV2FPT0WU
PC-14 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu1RnRwUUN3ME2yOE43PTdzIN88US=> MULTRW5ITVJ?
Calu-6 NV\2VJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf6RolKSzVyPUK1MlUxPzFizszN NXHydlhLW0GQR1XS
SJRH30 NWi3bYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrsdXJmUUN3ME2yOU43PDl4IN88US=> NVj5VJhMW0GQR1XS
ChaGo-K-1 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LwR2lEPTB;Mk[uNVYzQSEQvF2= M3T1TnNCVkeHUh?=
IA-LM MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrEeGFKSzVyPUK2MlM3PDVizszN M4D4XnNCVkeHUh?=
GP5d MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;1TWM2OD1{Nj60OFkyKM7:TR?= NHzuU2FUSU6JRWK=
NCI-H2291 M2OxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDqTWM2OD1{Nj62OVQyKM7:TR?= MmfIV2FPT0WU
BALL-1 NYS5[FhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm4TWM2OD1{Nj65N|k4KM7:TR?= MUjTRW5ITVJ?
HCC1954 NUPQXoN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GySGlEPTB;Mk[uPVgxQCEQvF2= NIrQbmZUSU6JRWK=
NCI-H2452 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ5LkSxOlMh|ryP MWjTRW5ITVJ?
LU-99A MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH3TWM2OD1{Nz61OVgzKM7:TR?= NVu0XI82W0GQR1XS
NTERA-S-cl-D1 M{XrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT6TWM2OD1{Nz63Nlk6KM7:TR?= MlfrV2FPT0WU
PANC-10-05 M2P1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ5Lke3O|Uh|ryP MYPTRW5ITVJ?
NCI-H2405 M3i2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPYTWM2OD1{Nz65N|g4KM7:TR?= MnizV2FPT0WU
MDA-MB-415 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\xeJg5UUN3ME2yPE41OTN5IN88US=> MXzTRW5ITVJ?
NCI-H2342 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjEZnJKSzVyPUK4MlUzQDFizszN M3PjPXNCVkeHUh?=
TGBC24TKB M1OyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPTWM2OD1{OD63NVE4KM7:TR?= MX3TRW5ITVJ?
LU-134-A MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HQfmlEPTB;MkiuPVI3OSEQvF2= M2jpXXNCVkeHUh?=
SCC-4 M4rCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTuTWM2OD1|MT6wOFk1KM7:TR?= NIiwTW5USU6JRWK=
Saos-2 NVLYOHpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTKTWM2OD1|MT65N|A3KM7:TR?= NWfYT4pxW0GQR1XS
RERF-LC-MS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLQToVKSzVyPUOyMlgzOzFizszN NFvyd4xUSU6JRWK=
M14 NX[1OY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXFTWM2OD1|Mj65O|Y1KM7:TR?= NVvETJZ7W0GQR1XS
HPAF-II MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTN|LkWwNVEh|ryP M2O2PHNCVkeHUh?=
NCI-H1755 Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3jc3VXUUN3ME2zOE4{OzB3IN88US=> NFLFfWJUSU6JRWK=
D-392MG M2K5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PSbGlEPTB;M{WuPFY4PCEQvF2= NHX3U3FUSU6JRWK=
A704 M3m5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjkN3NKSzVyPUO2MlA1OjdizszN M1:1RnNCVkeHUh?=
CP50-MEL-B NXq3dldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\PTWM2OD1|Nj6xPVEyKM7:TR?= NHPZfHZUSU6JRWK=
EW-18 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTScIZrUUN3ME2zOk41PTJizszN M1KzdHNCVkeHUh?=
WM-115 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTN4LkiwPVkh|ryP MYDTRW5ITVJ?
LU-65 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTN5LkG0NVch|ryP MmHHV2FPT0WU
NCI-H1563 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n5NmlEPTB;M{euNlQ5PCEQvF2= NV3OTmtVW0GQR1XS
DBTRG-05MG M2DQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL6UZc{UUN3ME2zPE4xPjlzIN88US=> MYXTRW5ITVJ?
NCI-H630 M4DTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTN6LkS3NVQh|ryP NWna[3dmW0GQR1XS
NCI-H1155 NIjIbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HhXmlEPTB;M{muNlQzKM7:TR?= Mn3BV2FPT0WU
OVACR-3 M3\iR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HNOGlEPTB;M{muPVE6PSEQvF2= M2HqW3NCVkeHUh?=
OAW-42 NWHxUFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe3N|BKSzVyPUSwMlQzPThizszN NFe1Z2hUSU6JRWK=
JVM-2 NFvJU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTIe2p4UUN3ME20NU4zPDF3IN88US=> MYPTRW5ITVJ?
C3A MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRzLkO0OFch|ryP M3W2SXNCVkeHUh?=
HT55 NITZNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD12Mj6yPFQyKM7:TR?= MkTkV2FPT0WU
OVCAR-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH2zfGtKSzVyPUSyMlI6PzRizszN MW\TRW5ITVJ?
MEG-01 NV;DVJBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR{LkS2NVYh|ryP M1fvNXNCVkeHUh?=
NCI-H82 NXexV4pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfPTWM2OD12Mz65PFkzKM7:TR?= M4rPfnNCVkeHUh?=
JEG-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT6U2lRUUN3ME20OE46PDdizszN NWDHNIJWW0GQR1XS
BPH-1 M1HJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTpTWM2OD12Nj6zPVk5KM7:TR?= MU\TRW5ITVJ?
MPP-89 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPHeYhDUUN3ME20O{4zQDl6IN88US=> Mn;XV2FPT0WU
ALL-PO MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rxTWlEPTB;NEeuOFE5QCEQvF2= NF7JWnBUSU6JRWK=
HT M4iycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDqTWM2OD12Nz60PVIh|ryP MXjTRW5ITVJ?
NCI-H2347 NXjkWZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfHeYVwUUN3ME20PE4xPzF3IN88US=> NXHiW5dIW0GQR1XS
A2780 NVflT3JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TSXmlEPTB;NEmuOFIzQCEQvF2= NYfHZXNWW0GQR1XS
KARPAS-299 NYnkXpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPTcHJKSzVyPUS5MlUyOTlizszN NHXkZYZUSU6JRWK=
NCI-H1651 NUT3ZoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHMTWM2OD12OT64PFIyKM7:TR?= M2PDc3NCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験:

[1]

+ 展開
  • 細胞株: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度: 0.01-1 μM
  • 反応時間: 24 hours
  • 実験の流れ:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量: 0-150 mg/kg
  • 投与方法: Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
Saline
いい結果が出るために、混じった後、直ちに使うと推めます。
20 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl

CAS No. 827022-32-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • 回答:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

相関CDK製品

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID